

TRANSCAN-3 JTC2021  
International  
Networking Event




This project is co-financed by the  
European Union and the Republic of Turkey  
Bu proje Avrupa Birliđi ve Türkiye Cumhuriyeti tarafından  
finanse edilmektedir



***Miguel Moreno***  
***AptusBiotech***

**[miguel.moreno@aptusbiotech.com](mailto:miguel.moreno@aptusbiotech.com)**



# Description of the Organization



- **Aptus Biotech** is a biotech start-up R&D performing SME whose main goal is the development of new biotechnological applications based on **aptamer** technology.
- **Aptamers** are artificial nucleic acid ligands (short single-stranded DNA or RNA) that present high association constants with target proteins, relatively easy and reproducible production and labelling, cost-effectiveness and stability during long-term storage.
- Aptus carried out the initial stages of the development and characterization of an **aptamer against TLR4**. AptaTargets purchased the molecule and initiated the ApTOLL program towards the treatment of acute ischemic stroke. Currently, the molecule is in **clinical trials phase IIa**.
- Nowadays, Aptus is seeking novel applications of our aptamer technology. Particularly, the company is focused on our **APTABREAST** project that aims to overcome the **preclinical phase** (non-regulatory and regulatory) by the Mnk1 aptamer (**apMNKQ2**) development for breast cancer novel **therapy**.

# Our Technology: Aptamers


## Aptamers: a promising technology in pharmacology

1. **Nucleic acids** capable of binding to specific target molecules due to the acquisition of a **stable 3D structure**.
2. **Selected *in vitro*** depending on the specificity of binding with a particular target from millions of random sequences.
3. Show relevant advantages and are a **clear alternative to antibodies**.



Specific recognition and stable binding

Aptamers' Advantages	Costs	Chemical synthesis
	Safety	Non-immunogenic
	Long half-life	Reversible denaturation
	Range	To a wide number of targets
	Other	Smaller size, stability and reproducibility



# Project Idea




Please indicate relevant JTC2021 aim and sub aims

**Aim 1: Identification and validation of tumour microenvironment (TME) subclasses and their contribution to the resistance mechanisms**

**Aim 2: Targeting TME to improve efficacy of immunotherapy in human patients.**

We offer our **APTAMER CUSTOM SERVICE** as a tool to generate novel tools targeting TME to improve immunotherapy efficacy





This project is co-financed by the  
European Union and the Republic of Turkey  
Bu proje Avrupa Birliđi ve Türkiye Cumhuriyeti tarafından  
finanse edilmektedir



# Miguel Moreno

## AptusBiotech CSO Spain

[miguel.moreno@aptusbiotech.com](mailto:miguel.moreno@aptusbiotech.com)

[www.aptusbiotech.com](http://www.aptusbiotech.com)

